Clinical Trials Logo

Myocardial Perfusion Imaging clinical trials

View clinical trials related to Myocardial Perfusion Imaging.

Filter by:

NCT ID: NCT06047028 Recruiting - Clinical trials for Myocardial Perfusion Imaging

'Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability

Start date: June 30, 2023
Phase:
Study type: Observational

Heart failure due to coronary artery disease represents a significant cause of mortality. The detection of patients eligible for bypass surgery is a pivotal concern. Nevertheless, the optimal approach for patient selection based on conventional imaging scans remains unclear. The proposed method (Hyperpolarized 13C MRI) has gained extensive use in evaluating in vivo metabolism. This method avoids ionizing radiation and provides critical insights into cardiac function. The feasibility study aims to investigate this method for patient selection before bypass surgery. This innovative imaging technique facilitates the identification of two simple molecules, bicarbonate and lactic acid, produced at high rates by normal heart metabolism. Both bicarbonate and lactate originate from the same precursor molecule, pyruvate. The data generated from this study holds the potential to refine diagnostic precision.

NCT ID: NCT04599192 Enrolling by invitation - Coronary Disease Clinical Trials

Fractional Flow Reserve and Instantaneous Free-wave Ratio Revascularization Strategies in Women

FiRST
Start date: April 19, 2019
Phase:
Study type: Observational [Patient Registry]

A real world study to evaluate outcomes in women based on guideline identified fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) cutoffs for ischemia (ischemia defined as FFR ≤ 0.80 and iFR ≤ 0.89).

NCT ID: NCT04465526 Completed - Myocardial Ischemia Clinical Trials

The Influence of Coronary Chronic Total Occlusion on Myocardial Perfusion on Computed Tomography

COPACABANA
Start date: February 1, 2020
Phase:
Study type: Observational

The COPACABANA study is designed as a single-centre, open, prospective trial aimed to assess the influence of coronary chronic total occlusion (CTO) on downstream myocardial ischemia via the novel computed tomography perfusion (CTP) imaging technique. To this end, consecutive patients with CTO of a major coronary artery scheduled to undergo percutaneous recanalization of occluded coronary artery based on clinical grounds, will undergo stress CTP using state-of-the-art dual-energy CT scanner at 2 time points (before and 3 months after successful restoration of flow in the CTO vessel).

NCT ID: NCT03937921 Recruiting - Clinical trials for Magnetic Resonance Imaging

Dotarem Evaluation for Myocardial Perfusion CMR

Start date: July 3, 2019
Phase:
Study type: Observational

The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for accurate quantitative perfusion evaluation. The purpose of this study is to compare two types of contrast that patients receive during cardiac MRI scans to visualize the blood flow in the cardiac muscle. Both contrasts are used in standard of care procedures, and the one administered for each patient will be randomly selected. The length of the MRI study all procedures are the same as the clinically indicated scan.

NCT ID: NCT03917199 Completed - Clinical trials for Coronary Artery Disease

Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study).

ULYSSES
Start date: November 2016
Phase:
Study type: Observational

The ULYSSES study is a single-center, prospective study aimed at evaluation of myocardial ischemia using regadenoson low-dose dynamic computed tomography myocardial perfusion imaging (CTP) in patients diagnosed with intermediate coronary artery stenoses in referrence to the magnetic resonance myocardial perfusion imaging (MR MPI).

NCT ID: NCT03864497 Completed - Liver Failure Clinical Trials

Myocardial Perfusion Imaging in Liver Transplantation Candidates

ExSPECT
Start date: September 2007
Phase:
Study type: Observational

The optimal screening strategy for assessment of coronary artery disease in patients with end-stage liver disease (ESLD) is unclear. Although consensus based guidelines support noninvasive stress testing prior to orthotopic liver transplantation (OLT), no prospective studies are available to inform the clinician on perioperative risk stratification. This observational cohort study was designed to determine the prognostic utility of single photon emission computed tomography (SPECT) imaging in OLT candidates.

NCT ID: NCT03180060 Completed - Coronary Disease Clinical Trials

Meta-Analysis of Stress Myocardial Perfusion Imaging

Start date: August 3, 2015
Phase: N/A
Study type: Observational

Background: Detection of coronary artery disease (CAD) is important due to its high prevalence and its medical and economic implications. Purpose: A systematic review of the diagnostic performance of stress echocardiography (Echo), SPECT, cardiac magnetic resonance (CMR), CT Perfusion (CTP) and PET versus invasive coronary angiography (ICA) or fractional flow reserve (FFR) using hierarchical summary ROC (HSROC) methods. Data Sources: MEDLINE, EMBASE and SCOPUS for literature published in English or Spanish from January 1970 to December 2015. Study Selection: For inclusion, studies had to meet the Cochrane guidelines, had to evaluate the sensitivity and specificity methods, and use ICA and/or FFR. Only those studies with STARD methodology ≥60% were included. Data Extraction: Ten investigators extracted patient and study characteristics and 4 resolved any disagreements.

NCT ID: NCT03173716 Completed - Clinical trials for Myocardial Perfusion Imaging

Real-Time Myocardial Perfusion Echocardiography in the ICU

Start date: September 28, 2017
Phase: Phase 4
Study type: Interventional

This study is being done to find out if and how much the use of RTMPE improves a provider's confidence in the diagnosis they assign. This is important because the use of RTMPE may decrease the need for any additional invasive testing.

NCT ID: NCT03150342 Recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Start date: May 8, 2017
Phase: N/A
Study type: Observational

Chest pain and myocardial ischemia are prevailing features in patients with hypertrophic cardiomyopathy (HCM). Recently introduced single-photon emission computed tomography (SPECT) cameras with solid-state cadmium-zinc-telluride (CZT) detectors have been shown to decrease imaging time and improved the imaging quality of gated myocardial perfusion imaging (MPI). The investigators also correlate the MPI parameters with echocardiographic parameters. This study is to examine the spatial distribution of stress perfusion abnormalities and tissue injury in patients with HCM using a CZT SPECT camera.

NCT ID: NCT03084562 Completed - Clinical trials for Myocardial Perfusion Imaging

Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT

REDUCE
Start date: May 3, 2017
Phase:
Study type: Observational

Myocardial perfusion scintigraphy is to evaluate coronary perfusion as well as heart muscle function. This examination takes place in two stages, one imaging at rest and one after a cardiac stress caused. This stress can be triggered as a first-line stress test. A pharmacological stress is proposed when stress test is not possible or contraindicated, Several drugs have a marketing authorization in this indication (adenosine, dipyridamole, regadenoson, dobutamine). Among them, the regadenoson is the most recent molecule. Marketed in France since 2013, it would allow a reduction of undesirable effects compared to other agents, especially adenosine. It is simple and quick to use thanks to a single dose administration. However, its cost is nearly 30 times higher than dipyridamole. In the investigational center, dipyridamole is currently the first-line pharmacological stress agent, whereas regadenoson is reserved for a limited number of doses, the indication of which must be justified (asthmatic patient or with severe COPD). Few studies in the literature specifically compare these two pharmacological agents (examination time, cost, tolerance) and the opinion on the use of regadenoson in the service is limited.